for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Hikma Pharmaceuticals Plc

HIK.L

Latest Trade

2,018.00GBp

Change

-27.00(-1.32%)

Volume

341,815

Today's Range

2,006.00

 - 

2,041.00

52 Week Range

2,006.00

 - 

2,703.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
2,045.00
Open
2,025.00
Volume
341,815
3M AVG Volume
6.88
Today's High
2,041.00
Today's Low
2,006.00
52 Week High
2,703.00
52 Week Low
2,006.00
Shares Out (MIL)
231.50
Market Cap (MIL)
4,734.14
Forward P/E
14.64
Dividend (Yield %)
1.85

Next Event

Full Year 2021 Hikma Pharmaceuticals PLC Earnings Release

Latest Developments

More

Hikma Sees FY Core Operating Margin Towards Top End Of 22% To 24%

Hikma Pharmaceuticals Reiterate FY Guidance

Hikma Pharmaceutical Agreed To Acquire Custopharm Inc From Water Street Healthcare Partners

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing, marketing and selling of a broad range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The Company's segments include Branded, Injectables, Generics and Others. The Company provides non-injectable and injectable generic medicines in the United States. It provides branded generic medicines and generic injectable products across the Middle East and North Africa (MENA). It also provides generic injectable medicines in Europe and other markets around the world. The Company's other businesses comprise Arab Medical Containers (AMC), a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.

Industry

Biotechnology & Drugs

Contact Info

1 New Burlington Place

W1S 2HR

United Kingdom

+44.20.73992760

https://www.hikma.com/

Executive Leadership

Said Samih Darwazah

Executive Chairman of the Board

Sigurdur Olafsson

Chief Executive Officer, Executive Director

Mazen Samih Talib Darwazah

Executive Vice Chairman of the Board, President of MENA

Khalid Nabilsi

Chief Financial Officer

Brian Hoffman

President, US Generics Division

Key Stats

1.69 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

2.1K

2019

2.2K

2020

2.3K

2021(E)

2.5K
EPS (USD)

2018

1.370

2019

1.500

2020

1.710

2021(E)

1.899
Price To Earnings (TTM)
13.85
Price To Sales (TTM)
2.66
Price To Book (MRQ)
2.81
Price To Cash Flow (TTM)
10.47
Total Debt To Equity (MRQ)
40.70
LT Debt To Equity (MRQ)
32.79
Return on Investment (TTM)
15.29
Return on Equity (TTM)
11.44

Latest News

Latest News

Drugmaker Hikma to buy U.S.-based Custopharm to boost needle-based treatments

Hikma Pharmaceuticals said on Monday it would buy U.S.-based sterile injectables firm Custopharm in a deal worth up to $425 million, as the generic medicines maker looks to strengthen its needle-based treatments unit in the United States.

Hikma Pharmaceuticals to buy U.S.-based injectables firm Custopharm

Hikma Pharmaceuticals said on Monday it would buy U.S.-based sterile injectables company Custopharm in a $375 million deal, as the generic medicine maker looks to strengthen its U.S. injectables business.

Supreme Court denies Amarin's bid to revive Vascepa drug patents

The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against generic drugmakers Hikma Pharmaceuticals PLC and Dr. Reddy's Laboratories Ltd.

U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents

The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against generic drugmakers Hikma Pharmaceuticals PLC and Dr. Reddy's Laboratories Ltd.

Hikma, GSK end talks over potential Egypt, Tunisia assets deal

Hikma Pharmaceuticals and GlaxoSmithKline have ended talks over a potential buyout deal for the latter's pharmaceutical, consumer commercialisation and manufacturing business in Egypt and its drugs business in Tunisia, the companies said on Thursday.

UPDATE 2-UK's Hikma misses profit estimate, disappoints on 2021 outlook, share tumbles

* Shares drop nearly 7% (Recasts, adds shares, CEO and analyst comments)

UK's Hikma sees higher 2021 sales, posts increase in FY profit

Britain's Hikma Pharmaceuticals said on Thursday it expects higher sales for all of its three businesses for the new year, after it posted a rise in annual core operating profit driven by its injectables and generics segments.

Hikma plans to buy some of GSK's assets in Egypt, Tunisia

Hikma Pharmaceuticals said on Tuesday it was planning to buy GSK's stake in some assets including the drugmaker's pharmaceutical, consumer commercialisation and manufacturing business in Egypt and its drugs business in Tunisia.

UPDATE 1-NY governor investigates price jump in six drugs during pandemic

New York Governor Andrew Cuomo said on Thursday the Department of Financial Services was investigating into a price jump of about 60% to 1,350% in six drugs during the COVID-19 pandemic.

UK's Hikma making Gilead's COVID-19 drug remdesivir to increase supply

Britain's Hikma Pharmaceuticals said on Friday it has started manufacturing Gilead's antiviral drug remdesivir under contract in Portugal, as the U.S. company outsources to increase availability of the COVID-19 treatment.

UPDATE 2-Hikma shares jump after improved sales outlook, COVID-19 drug deal

* Shares jump 11%, biggest pct gainer on FTSE 100 (Writes through with Gilead deal, CEO, analyst comment and shares)

UK's Hikma starts manufacturing COVID-19 treatment remdesivir for Gilead

Hikma Pharmaceuticals has started manufacturing remdesivir, an approved treatment for COVID-19 from U.S.-based Gilead, for an undisclosed amount at its facility in Portugal, the British company's chief executive officer said.

Hikma raises annual sales outlook for top two units; profit gains on critical drug demand

Hikma Pharmaceuticals Plc revised its annual sales outlook for two of its biggest divisions on Friday and reported higher first-half profit, as hospitals and distributors stocked up on critical medicines during the COVID-19 pandemic.

BRIEF-Hikma Pharmaceuticals Says Jochen Gann Has Resigned His Directorship Of Co

* HIKMA - JOCHEN GANN HAS RESIGNED HIS DIRECTORSHIP OF HIKMA WITH IMMEDIATE EFFECT

South Africa's Aspen could supply 10 million dexamethasone pills in COVID-19 crisis

South African pharmaceutical major Aspen could provide 10 million dexamethasone tablets within a month, Chief Executive Stephen Saad said on Tuesday after the World Health Organisation cautioned about the drug's supply.

Deals of the day-Mergers and acquisitions

The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

Hikma's major investor to exit nearly 1 bln pound stake in drugmaker

Boehringer Ingelheim, a major shareholder in Hikma Pharmaceuticals <HIK.L>, is exiting the London-listed drugmaker by selling most of its nearly one billion pound stake to institutional investors and the rest back to the company, Hikma said on Monday.

Germany's pharma firm Boehringer to offload stake in drugmaker Hikma

Hikma Pharmaceuticals said on Monday investor Boehringer Ingelheim would sell up to 28 million shares in the London-listed drugmaker, or shares worth about 700 million pounds ($871.43 million), according to a bookrunner for the deal.

BRIEF-Boehringer Ingelheim Intends To Sell Up To About 28 Mln Shares In Hikma

* J.P. MORGAN SEC PLC HIKMA PHARMACEUTICAL - PROPOSED PLACING IN HIKMA PHARMACEUTICALS PLC

BRIEF-Sun Pharma, Hikma Sign Exclusive Licensing Deal For Ilumya For MENA Region

* SUN PHARMA AND HIKMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR ILUMYA FOR MIDDLE EAST & NORTH AFRICA REGIONS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up